KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Capital Leases (2020 - 2025)

Novavax (NVAX) has 9 years of Capital Leases data on record, last reported at $2.3 million in Q3 2025.

  • For Q3 2025, Capital Leases fell 95.83% year-over-year to $2.3 million; the TTM value through Sep 2025 reached $2.3 million, down 95.83%, while the annual FY2024 figure was $53.7 million, 3.93% down from the prior year.
  • Capital Leases reached $2.3 million in Q3 2025 per NVAX's latest filing, down from $52.4 million in the prior quarter.
  • Across five years, Capital Leases topped out at $55.9 million in Q4 2023 and bottomed at $2.3 million in Q3 2025.
  • Average Capital Leases over 5 years is $39.0 million, with a median of $52.4 million recorded in 2025.
  • Peak YoY movement for Capital Leases: skyrocketed 79.02% in 2023, then tumbled 95.83% in 2025.
  • A 5-year view of Capital Leases shows it stood at $9.2 million in 2021, then soared by 239.8% to $31.2 million in 2022, then surged by 79.02% to $55.9 million in 2023, then decreased by 3.93% to $53.7 million in 2024, then plummeted by 95.78% to $2.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Leases were $2.3 million in Q3 2025, $52.4 million in Q2 2025, and $53.1 million in Q1 2025.